Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter ended June 30, 2024. The company posted a robust growth in PAT for Q1FY25 at Rs. 86 crore, a jump of 172% as compared to Rs. 32 crore in Q1 FY24. The company’s quarterly revenue from operations rose by 43% to Rs. 651 crore as against Rs. 455 crore recorded in Q1 FY24.

Commenting on the results, Maulik Patel, Chairman and Managing Director, Epigral said: “Epigral witnessed highest ever quarterly revenue of Rs. 651 crore in the quarter under review. The company delivered volume growth of 29% YoY and 14% QoQ; this growth is primarily attributed to efficient utilization of capacities and also volume from new projects commissioned. Revenue contribution from Derivatives & Specialty business rose sharply and stood at 53% in Q1FY25 vs 37% in Q1FY24”.

“In the April to June 2024 quarter, we commissioned CPVC Resin and Compound facility and by the end of current quarter we expect to commission Chlorotoluenes Value Chain facility, both these projects will drive growth for Epigral in FY2025 and FY2026. We are moving in line with our long term vision to become fully integrated complex catering to diversified industries and grow consistently to create value for our stakeholders.” Mr. Patel added.

Q1FY25 Operational Highlights

* Volume grew 29% YoY and 14% QoQ. Major growth comes from Derivatives & Specialty business

* Capacity utilization stood at 83% in Q1FY25 vs 71% in Q1FY24

* QoQ realizations dropped for all the products in range of 1% to 7%, except for Caustic Soda 

Q1FY25 Financial Highlights

* Highest ever quarterly revenue of Rs. 651 Cr, growth of 43% YoY and 24% QoQ on account of volume growth

* Revenue contribution from Derivatives & Specialty segment increased to 53% in Q1FY25 vs 37% in Q1FY24

* EBITDA stood at Rs. 176 crore vs Rs. 95 crore in Q1FY24. Growth of 85% YoY and 14% QoQ

* EBIDTA margin stood at 27% in Q1FY25 vs 21% in Q1FY24 on account of increase in utilization and volume contribution from new projects commissioned

* PAT stood at Rs. 86 crore, PAT margin stood at 13% vs 7% in Q1FY24

* ROCE stood at 21% as on 30th June 2024 vs 17% as on 31st March 2024

* Net Debt / EBITDA stood at 1.59x as on 30th June 2024 vs 1.99x as on 31st March 2024 

Strategic Update for Q1FY2025

* On 3rd April 2024, Epigral commissioned additional CPVC capacity of 45,000 TPA to reach total capacity of 75,000 TPA

* Epigral commissioned CPVC Compound facility in June 2024

* Chlorotoluenes Value Chain project is expected to get commission in Q2FY25